{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T01:13:08Z","timestamp":1783905188193,"version":"3.55.0"},"reference-count":59,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Hosp Pharm"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Patients with end stage renal disease undergoing haemodialysis commonly have multimorbidity, which in turn leads to polypharmacy. Additionally, end stage renal disease limits the choice and dosage of medicines. In Namibia, patients can access care at privately run dialysis centres. Patients seen at state-run health facilities in need of renal care from the dialysis centres, have their renal care costs covered by the Ministry of Health and Social Services.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim:<\/jats:title>\n                    <jats:p>The main purpose of this study was to assess the appropriateness of medication therapy among patients with end stage renal disease who underwent haemodialysis at two dialysis centres in Windhoek. Further, the study also compared prescribing patterns between state-funded and privately funded haemodialysis patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      A retrospective, quantitative and analytic design involving the review of clinical records of patients attending haemodialysis at the two dialysis centres. The types of medicines prescribed were classified according to the Anatomical Therapeutic Chemical (ATC) classification. The\n                      <jats:italic toggle=\"yes\">Drug Prescribing in Renal Failure Handbook<\/jats:italic>\n                      was used as a primary reference for assessing the appropriateness of renal dosage adjustment. The primary references used to check for the appropriateness of medication choice were the\n                      <jats:italic toggle=\"yes\">KDIGO Clinical Practice Guidelines<\/jats:italic>\n                      . Other references were used as secondary sources.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 147 patients\u2019 clinical records were reviewed and included in this study. About one-third (33.3%) of patients had at least one or more inappropriately selected medicines. Most patients 82.0% (n = 121) had at least one or more inappropriately renally adjusted medicines. More privately funded patients were prescribed Vitamin D or its analogues (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .001), phosphate binders (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .001), antithrombotic agents (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .001), lipid modifying agents (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .001), and angiotensin receptor blockers (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>As anticipated, patients on haemodialysis were being managed with a relatively large number of medicines. Renal dosage adjustment could be improved to ensure patient safety. The differences in the prescribing of vital medicines such as phosphate binders, between state funded versus privately funded patients warrants further investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/00185787251403015","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T07:05:23Z","timestamp":1767683123000},"page":"356-365","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Assessment of Appropriate Prescribing in Maintenance Haemodialysis and Comparison of Prescribing Patterns Between State- and Privately-Funded Patients: A Retrospective Review"],"prefix":"10.1177","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7189-1703","authenticated-orcid":false,"given":"Martha","family":"Kampanza","sequence":"first","affiliation":[{"name":"University of Namibia, Windhoek, Namibia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger Karel","family":"Verbeeck","sequence":"additional","affiliation":[{"name":"University of Namibia, Windhoek, Namibia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Jonkman","sequence":"additional","affiliation":[{"name":"University of Namibia, Windhoek, Namibia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mwangana","family":"Mubita","sequence":"additional","affiliation":[{"name":"University of Namibia, Windhoek, Namibia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61601-9"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.30881\/beij.00005"},{"key":"e_1_3_3_4_2","unstructured":"Hashmi MF Benjamin O Lappin SL. End-Stage Renal Disease. Accessed August 1 2023. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK499861\/End-Stage Renal Disease"},{"key":"e_1_3_3_5_2","unstructured":"World Health Organization. Namibia Hypertension Profile. Accessed February 18 2025. https:\/\/www.who.int\/publications\/m\/item\/hypertension-nam-2023-country-profile"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2013.09.007"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00340118"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-009-0678-8"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1177\/2054358120912652"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1159\/000520028"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.2147\/CPAA.S147835"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy11020043"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.18231\/j.ijpp.2020.021"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.4103\/epj.epj_89_22"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.18203\/2319-2003.ijbcp20171106"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/hdi.13171"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2023.11.012"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12155080"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-018-0651-7"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.4314\/tjpr.v16i3.27"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/1504371"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0278563"},{"key":"e_1_3_3_23_2","unstructured":"Deutsche Gesellschaft f\u00fcr Internationale Zusammenarbeit (GIZ) GmbH-German Federal Ministry for Economic Cooperation and Development (BMZ). Sector Brief Namibia: Health. Accessed September 10 2024. https:\/\/www.giz.de\/en\/downloads\/giz2023-sector-brief-namibia-health.pdf"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.4102\/phcfm.v12i1.2242"},{"key":"e_1_3_3_25_2","unstructured":"The Namibian Parliament and National Assembly. Vote 13 Budget Statement: Statement by DR Kalumbi Shangula (MP) Minister of Health and Social Services on the Occasion of the Introduction of Vote 13 (Health and Social Services) for the 2024\/ 2025 Financial Year. Accessed September 2 2024. https:\/\/www.parliament.na\/wpcontent\/uploads\/2021\/07\/Vote13_Health.pdf"},{"key":"e_1_3_3_26_2","unstructured":"World Bank Group. The World Bank in Namibia. Accessed February 19 2025. https:\/\/www.worldbank.org\/en\/country\/namibia\/overview"},{"key":"e_1_3_3_27_2","unstructured":"Namibia Statistics Agency. Namibia 2023 Population and Housing Census Labour Force Report. Accessed February 19 2023. https:\/\/census.nsanamibia.com\/wp-content\/uploads\/2025\/01\/2023-PHC-Labourforce-Report.pdf"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2020.11.015"},{"key":"e_1_3_3_29_2","unstructured":"World Health Organization. Anatomical Therapeutic Chemical (ATC) Classification: Structure and Principles. Accessed May 28 2023. https:\/\/www.who.int\/tools\/atc-ddd-toolkit\/atc-classification"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1201\/9781315379456"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/med\/9780199644766.001.0001"},{"key":"e_1_3_3_32_2","volume-title":"British National Formulary","author":"Joint Formulary Committee","year":"2019","unstructured":"Joint Formulary Committee. British National Formulary. 78th ed. British Medical Association and Royal Pharmaceutical Society of Great Britain; 2019.","edition":"78"},{"key":"e_1_3_3_33_2","volume-title":"South African Medicines Formulary","author":"Rossiter D","year":"2020","unstructured":"Rossiter D, ed. South African Medicines Formulary. 13th ed. Health and Medical Publishing Group; 2020.","edition":"13"},{"key":"e_1_3_3_34_2","unstructured":"Electronic Medicines Compendium (EMC). Datapharm Ltd; 2024. Accessed May 23 2023. https:\/\/www.medicines.org.uk\/emc#gref"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.01.046"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.05.021"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.kisu.2017.04.001"},{"key":"e_1_3_3_38_2","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for anemia in chronic kidney disease. Kidney Int. 2012;2(4):1-12. Accessed May 23 2023. https:\/\/kdigo.org\/wp-content\/uploads\/2016\/10\/KDIGO-2012-Anemia-Guideline-English.pdf"},{"key":"e_1_3_3_39_2","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Accessed May 24 2023. https:\/\/kdigo.org\/wp-content\/uploads\/2022\/10\/KDIGO-2022-Clinical-Practice-Guideline-for-Diabetes-Management-in-CKD.pdf"},{"key":"e_1_3_3_40_2","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO). Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease. 2013. Accessed June 13 2023. https:\/\/kdigo.org\/wp-content\/uploads\/2017\/02\/KDIGO-2013-Lipids-Guideline-English.pdf"},{"key":"e_1_3_3_41_2","volume-title":"IBM SPSS Statistics for Windows","author":"IBM Corp","unstructured":"IBM Corp. Released 2019. IBM SPSS Statistics for Windows, Version 26.0. Armonk, NY: IBM Corp."},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2024.1426953"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfw138"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158677"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.13449"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1412"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.46405\/ejms.v2i1.39"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-015-0155-9"},{"issue":"10","key":"e_1_3_3_49_2","article-title":"Clinical pharmacy and pharmaceutical care: a need to homogenize the concepts","volume":"74","author":"Ahmed SI","year":"2010","unstructured":"Ahmed SI, Hasan SS, Hassali MA. Clinical pharmacy and pharmaceutical care: a need to homogenize the concepts. Am J Pharm Educ. 2010;74(10):193g.","journal-title":"Am J Pharm Educ"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14589"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2020.01.23"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-023-03210-5"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfu070"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-022-01453-0"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.18549\/PharmPract.2016.03.785"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2020.02.006"},{"key":"e_1_3_3_57_2","unstructured":"Republic of Namibia Ministry of Health and Social Services. Namibia Essential Medicines List. 2016. Accessed September 23 2024. https:\/\/platform.who.int\/docs\/default-source\/mca-documents\/policy-documents\/essential-medicines-and-equipment\/NAM-CH-43-01-EMD-2016-eng-Namibia-Essential-Medicines-List-2016.pdf"},{"issue":"2","key":"e_1_3_3_58_2","first-page":"100","article-title":"Calcium and Calcium salts","volume":"65","author":"Trailokya A","year":"2017","unstructured":"Trailokya A, Srivastava A, Bhole M, Zalte N. Calcium and Calcium salts. J Assoc Physicians India. 2017;65(2):100-103.","journal-title":"J Assoc Physicians India"},{"key":"e_1_3_3_59_2","unstructured":"National Kidney Foundation n\u2019s Kidney Disease Outcomes Quality Initiative (KDOQI). Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. 2017. Accessed February 8 2024. http:\/\/kidneyfoundation.cachefly.net\/professionals\/KDOQI\/guidelines_bone\/index.htm"},{"key":"e_1_3_3_60_2","volume-title":"Namibia Standard Treatment Guidelines","author":"Republic of Namibia Ministry of Health and Social Services","year":"2021","unstructured":"Republic of Namibia Ministry of Health and Social Services. Namibia Standard Treatment Guidelines. 2nd ed. Tertiary Health Care and Clinical Support Services Division; 2021.","edition":"2"}],"container-title":["Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00185787251403015","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/00185787251403015","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00185787251403015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:44:38Z","timestamp":1783903478000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/00185787251403015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":59,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1177\/00185787251403015"],"URL":"https:\/\/doi.org\/10.1177\/00185787251403015","relation":{},"ISSN":["0018-5787","1945-1253"],"issn-type":[{"value":"0018-5787","type":"print"},{"value":"1945-1253","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]}}}